JP2007502815A - Ppar調節因子 - Google Patents
Ppar調節因子 Download PDFInfo
- Publication number
- JP2007502815A JP2007502815A JP2006523861A JP2006523861A JP2007502815A JP 2007502815 A JP2007502815 A JP 2007502815A JP 2006523861 A JP2006523861 A JP 2006523861A JP 2006523861 A JP2006523861 A JP 2006523861A JP 2007502815 A JP2007502815 A JP 2007502815A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- mmol
- hydrogen
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title claims abstract description 42
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 123
- 239000012453 solvate Substances 0.000 claims abstract description 95
- 238000011282 treatment Methods 0.000 claims abstract description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 43
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 34
- 230000002265 prevention Effects 0.000 claims abstract description 17
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 16
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 16
- 208000008589 Obesity Diseases 0.000 claims abstract description 13
- 235000020824 obesity Nutrition 0.000 claims abstract description 13
- 206010020772 Hypertension Diseases 0.000 claims abstract description 11
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 11
- 230000001404 mediated effect Effects 0.000 claims abstract description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 286
- 239000000203 mixture Substances 0.000 claims description 237
- -1 Cyano, Hydroxyl Chemical group 0.000 claims description 170
- 229910052739 hydrogen Inorganic materials 0.000 claims description 130
- 239000001257 hydrogen Substances 0.000 claims description 130
- 150000002431 hydrogen Chemical class 0.000 claims description 94
- 229910052760 oxygen Inorganic materials 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 91
- 125000003118 aryl group Chemical group 0.000 claims description 72
- 125000005843 halogen group Chemical group 0.000 claims description 62
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 60
- 125000001072 heteroaryl group Chemical group 0.000 claims description 59
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 54
- 125000001188 haloalkyl group Chemical group 0.000 claims description 53
- 239000000126 substance Substances 0.000 claims description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 48
- 229910052717 sulfur Inorganic materials 0.000 claims description 48
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 45
- 125000004104 aryloxy group Chemical group 0.000 claims description 44
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 44
- 125000001424 substituent group Chemical group 0.000 claims description 42
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 36
- 201000010099 disease Diseases 0.000 claims description 35
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 35
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 34
- 125000004043 oxo group Chemical group O=* 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 31
- 102000004877 Insulin Human genes 0.000 claims description 30
- 108090001061 Insulin Proteins 0.000 claims description 30
- 229940125396 insulin Drugs 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 29
- 108010016731 PPAR gamma Proteins 0.000 claims description 28
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 27
- 239000008103 glucose Substances 0.000 claims description 27
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- 206010022489 Insulin Resistance Diseases 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 16
- 239000008280 blood Substances 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 15
- 229910052801 chlorine Inorganic materials 0.000 claims description 15
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 13
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 10
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 10
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 10
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 10
- 229940100389 Sulfonylurea Drugs 0.000 claims description 10
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 150000003536 tetrazoles Chemical class 0.000 claims description 10
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 9
- 229940125753 fibrate Drugs 0.000 claims description 9
- 229940124530 sulfonamide Drugs 0.000 claims description 9
- 150000003456 sulfonamides Chemical class 0.000 claims description 9
- 229940123208 Biguanide Drugs 0.000 claims description 8
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 8
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 8
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims description 7
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 229940122355 Insulin sensitizer Drugs 0.000 claims description 7
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 7
- 150000003857 carboxamides Chemical class 0.000 claims description 7
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 6
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims description 6
- 229940122199 Insulin secretagogue Drugs 0.000 claims description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 6
- 239000000883 anti-obesity agent Substances 0.000 claims description 6
- 229940125710 antiobesity agent Drugs 0.000 claims description 6
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
- 150000001721 carbon Chemical class 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229950004994 meglitinide Drugs 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000001544 thienyl group Chemical group 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 229940123324 Acyltransferase inhibitor Drugs 0.000 claims description 5
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 5
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 5
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 claims description 5
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims description 5
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims description 5
- 239000002404 acyltransferase inhibitor Substances 0.000 claims description 5
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 5
- 125000002541 furyl group Chemical group 0.000 claims description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000002971 oxazolyl group Chemical group 0.000 claims description 5
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 208000032841 Bulimia Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 239000003524 antilipemic agent Substances 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 206010033799 Paralysis Diseases 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 208000021090 palsy Diseases 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 125000005841 biaryl group Chemical group 0.000 claims 10
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 6
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 2
- 208000022531 anorexia Diseases 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 21
- 102000005962 receptors Human genes 0.000 abstract description 11
- 108020003175 receptors Proteins 0.000 abstract description 11
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 6
- 206010053567 Coagulopathies Diseases 0.000 abstract description 3
- 208000015294 blood coagulation disease Diseases 0.000 abstract description 3
- 239000003614 peroxisome proliferator Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 518
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 425
- 235000019439 ethyl acetate Nutrition 0.000 description 229
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 170
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 170
- 235000002639 sodium chloride Nutrition 0.000 description 159
- 239000000243 solution Substances 0.000 description 127
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 114
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 108
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 107
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 85
- 235000019341 magnesium sulphate Nutrition 0.000 description 85
- 239000011780 sodium chloride Substances 0.000 description 85
- 229920006395 saturated elastomer Polymers 0.000 description 82
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 76
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 73
- 238000000746 purification Methods 0.000 description 54
- 239000000377 silicon dioxide Substances 0.000 description 53
- 238000003818 flash chromatography Methods 0.000 description 52
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 43
- 239000012074 organic phase Substances 0.000 description 42
- 239000007787 solid Substances 0.000 description 37
- 239000011734 sodium Substances 0.000 description 36
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 34
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 33
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 239000012230 colorless oil Substances 0.000 description 32
- 239000012044 organic layer Substances 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 30
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 30
- 235000019441 ethanol Nutrition 0.000 description 29
- 238000005481 NMR spectroscopy Methods 0.000 description 28
- 102000000536 PPAR gamma Human genes 0.000 description 28
- 229910000024 caesium carbonate Inorganic materials 0.000 description 28
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 27
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 26
- 239000000706 filtrate Substances 0.000 description 24
- 239000003921 oil Substances 0.000 description 24
- 235000019198 oils Nutrition 0.000 description 24
- 239000007864 aqueous solution Substances 0.000 description 22
- 238000003756 stirring Methods 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 150000005347 biaryls Chemical group 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 15
- JCIXHLTWENDKBP-LBPRGKRZSA-N methyl 3-[4-[(3s)-3-methylsulfonyloxybutoxy]phenyl]propanoate Chemical compound COC(=O)CCC1=CC=C(OCC[C@H](C)OS(C)(=O)=O)C=C1 JCIXHLTWENDKBP-LBPRGKRZSA-N 0.000 description 14
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 102000023984 PPAR alpha Human genes 0.000 description 13
- 239000012141 concentrate Substances 0.000 description 13
- 235000008504 concentrate Nutrition 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- HDNRAPAFJLXKBV-UHFFFAOYSA-N 1-ethyl-4-methoxybenzene Chemical compound CCC1=CC=C(OC)C=C1 HDNRAPAFJLXKBV-UHFFFAOYSA-N 0.000 description 12
- 239000000556 agonist Substances 0.000 description 12
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
- 108010010234 HDL Lipoproteins Proteins 0.000 description 9
- 102000015779 HDL Lipoproteins Human genes 0.000 description 9
- 108010015181 PPAR delta Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 9
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical group CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 241000282412 Homo Species 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 229920000728 polyester Polymers 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- MAYRGUWEQUNSSQ-UHFFFAOYSA-N [5-ethyl-2-(4-hydroxybutan-2-yloxy)phenyl]-phenylmethanone Chemical compound CCC1=CC=C(OC(C)CCO)C(C(=O)C=2C=CC=CC=2)=C1 MAYRGUWEQUNSSQ-UHFFFAOYSA-N 0.000 description 7
- 239000013543 active substance Substances 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- XUTNAMGAXWLQKL-ZDUSSCGKSA-N ethyl 2-[2-methyl-4-[(3s)-3-methylsulfonyloxybutoxy]phenyl]sulfanylacetate Chemical compound CCOC(=O)CSC1=CC=C(OCC[C@H](C)OS(C)(=O)=O)C=C1C XUTNAMGAXWLQKL-ZDUSSCGKSA-N 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229940125542 dual agonist Drugs 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 229960002297 fenofibrate Drugs 0.000 description 6
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 239000008298 dragée Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000019260 propionic acid Nutrition 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- DQIZATBCQWTYLF-UHFFFAOYSA-N 3-phenoxy-5-(trifluoromethyl)-1h-pyridin-2-one Chemical compound OC1=NC=C(C(F)(F)F)C=C1OC1=CC=CC=C1 DQIZATBCQWTYLF-UHFFFAOYSA-N 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003472 antidiabetic agent Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 230000003301 hydrolyzing effect Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- LEVJVKGPFAQPOI-UHFFFAOYSA-N phenylmethanone Chemical compound O=[C]C1=CC=CC=C1 LEVJVKGPFAQPOI-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XAVFMOSJCDSLCQ-UHFFFAOYSA-N 2-bromo-4-ethylphenol Chemical compound CCC1=CC=C(O)C(Br)=C1 XAVFMOSJCDSLCQ-UHFFFAOYSA-N 0.000 description 3
- GCNBWRATGRJJKH-UHFFFAOYSA-N 3-benzoyl-5-chloro-1h-pyridin-2-one Chemical compound OC1=NC=C(Cl)C=C1C(=O)C1=CC=CC=C1 GCNBWRATGRJJKH-UHFFFAOYSA-N 0.000 description 3
- BELZKJMEGXSOLM-UHFFFAOYSA-N 5-chloro-3-phenoxy-1h-pyridin-2-one Chemical compound OC1=NC=C(Cl)C=C1OC1=CC=CC=C1 BELZKJMEGXSOLM-UHFFFAOYSA-N 0.000 description 3
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 3
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 3
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- UKERDACREYXSIV-UHFFFAOYSA-N N-methoxy-N-methylbenzamide Chemical compound CON(C)C(=O)C1=CC=CC=C1 UKERDACREYXSIV-UHFFFAOYSA-N 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 150000004283 biguanides Chemical class 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- DGNAJVAWILDFLL-UHFFFAOYSA-N cyclopropyl-(5-ethyl-2-hydroxyphenyl)methanone Chemical compound CCC1=CC=C(O)C(C(=O)C2CC2)=C1 DGNAJVAWILDFLL-UHFFFAOYSA-N 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- GQKQYMBQHKXEIT-UHFFFAOYSA-N ethyl 2-methyl-2-[4-(3-methylsulfonyloxybutoxy)phenoxy]propanoate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(OCCC(C)OS(C)(=O)=O)C=C1 GQKQYMBQHKXEIT-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- JCIXHLTWENDKBP-UHFFFAOYSA-N methyl 3-[4-(3-methylsulfonyloxybutoxy)phenyl]propanoate Chemical compound COC(=O)CCC1=CC=C(OCCC(C)OS(C)(=O)=O)C=C1 JCIXHLTWENDKBP-UHFFFAOYSA-N 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 108020004017 nuclear receptors Proteins 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 150000001467 thiazolidinediones Chemical class 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- LKKXIDOZYAXCDD-UHFFFAOYSA-N (2-methoxy-5-propan-2-ylphenyl)-phenylmethanone Chemical compound COC1=CC=C(C(C)C)C=C1C(=O)C1=CC=CC=C1 LKKXIDOZYAXCDD-UHFFFAOYSA-N 0.000 description 2
- FNPYYKDPPUYTFA-UHFFFAOYSA-N (5-chloro-2-methoxypyridin-3-yl)-phenylmethanone Chemical compound COC1=NC=C(Cl)C=C1C(=O)C1=CC=CC=C1 FNPYYKDPPUYTFA-UHFFFAOYSA-N 0.000 description 2
- PJINMFJTYOUNLP-UHFFFAOYSA-N (5-cyclopropyl-2-hydroxyphenyl)-phenylmethanone Chemical compound OC1=CC=C(C2CC2)C=C1C(=O)C1=CC=CC=C1 PJINMFJTYOUNLP-UHFFFAOYSA-N 0.000 description 2
- MWUDNGAYLDTDNX-UHFFFAOYSA-N (5-cyclopropyl-2-methoxyphenyl)-phenylmethanone Chemical compound COC1=CC=C(C2CC2)C=C1C(=O)C1=CC=CC=C1 MWUDNGAYLDTDNX-UHFFFAOYSA-N 0.000 description 2
- OYPPRNFDAGPGBZ-UHFFFAOYSA-N 1-cyclopropyl-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C1CC1 OYPPRNFDAGPGBZ-UHFFFAOYSA-N 0.000 description 2
- STLXATYPFWJECC-UHFFFAOYSA-N 1-methoxy-2-phenoxy-4-propan-2-ylbenzene Chemical compound COC1=CC=C(C(C)C)C=C1OC1=CC=CC=C1 STLXATYPFWJECC-UHFFFAOYSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- YRAJNWYBUCUFBD-UHFFFAOYSA-N 2,2,6,6-tetramethylheptane-3,5-dione Chemical compound CC(C)(C)C(=O)CC(=O)C(C)(C)C YRAJNWYBUCUFBD-UHFFFAOYSA-N 0.000 description 2
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 2
- XKVLYNWOABPZJR-UHFFFAOYSA-N 2-(5-ethyl-2-methoxyphenyl)-1,3-thiazole Chemical compound CCC1=CC=C(OC)C(C=2SC=CN=2)=C1 XKVLYNWOABPZJR-UHFFFAOYSA-N 0.000 description 2
- VPDXTNZWHRBQJL-UHFFFAOYSA-N 2-bromo-4-ethyl-1-methoxybenzene Chemical compound CCC1=CC=C(OC)C(Br)=C1 VPDXTNZWHRBQJL-UHFFFAOYSA-N 0.000 description 2
- KHOXTJVPNWYPKI-UHFFFAOYSA-N 2-phenoxy-4-propan-2-ylphenol Chemical compound CC(C)C1=CC=C(O)C(OC=2C=CC=CC=2)=C1 KHOXTJVPNWYPKI-UHFFFAOYSA-N 0.000 description 2
- XIMDCNRUDTUQFJ-QFIPXVFZSA-N 3-[2-methyl-4-[(3s)-3-(2-phenoxy-4-propan-2-ylphenoxy)butoxy]phenyl]propanoic acid Chemical compound C([C@H](C)OC1=CC=C(C=C1OC=1C=CC=CC=1)C(C)C)COC1=CC=C(CCC(O)=O)C(C)=C1 XIMDCNRUDTUQFJ-QFIPXVFZSA-N 0.000 description 2
- LAFHAGFHBUVCIQ-SFHVURJKSA-N 3-[4-[(3s)-3-(3-benzoyl-5-chloropyridin-2-yl)oxybutoxy]-2-methylphenyl]propanoic acid Chemical compound C([C@H](C)OC=1C(=CC(Cl)=CN=1)C(=O)C=1C=CC=CC=1)COC1=CC=C(CCC(O)=O)C(C)=C1 LAFHAGFHBUVCIQ-SFHVURJKSA-N 0.000 description 2
- QNTSQSFJMIOVQR-FQEVSTJZSA-N 3-[4-[(3s)-3-(4-ethyl-2-pyridin-3-ylphenoxy)butoxy]-2-methylphenyl]propanoic acid Chemical compound C([C@H](C)OC1=CC=C(C=C1C=1C=NC=CC=1)CC)COC1=CC=C(CCC(O)=O)C(C)=C1 QNTSQSFJMIOVQR-FQEVSTJZSA-N 0.000 description 2
- NAMKLBHSYDFYSO-IBGZPJMESA-N 3-[4-[(3s)-3-(4-ethyl-2-thiophen-3-ylphenoxy)butoxy]-2-methylphenyl]propanoic acid Chemical compound C([C@H](C)OC1=CC=C(C=C1C1=CSC=C1)CC)COC1=CC=C(CCC(O)=O)C(C)=C1 NAMKLBHSYDFYSO-IBGZPJMESA-N 0.000 description 2
- MBABYUYWUAQXJC-UHFFFAOYSA-N 3-[4-[3-(3-benzoyl-5-ethylpyridin-2-yl)oxybutoxy]-2-methylphenyl]propanoic acid Chemical compound C=1C=CC=CC=1C(=O)C1=CC(CC)=CN=C1OC(C)CCOC1=CC=C(CCC(O)=O)C(C)=C1 MBABYUYWUAQXJC-UHFFFAOYSA-N 0.000 description 2
- PZBAIBWKDJATGL-UHFFFAOYSA-N 3-benzoyl-5-(trifluoromethyl)-1h-pyridin-2-one Chemical compound OC1=NC=C(C(F)(F)F)C=C1C(=O)C1=CC=CC=C1 PZBAIBWKDJATGL-UHFFFAOYSA-N 0.000 description 2
- MTQIDHMTVXPDIB-UHFFFAOYSA-N 3-benzoyl-5-ethyl-1h-pyridin-2-one Chemical compound CCC1=CN=C(O)C(C(=O)C=2C=CC=CC=2)=C1 MTQIDHMTVXPDIB-UHFFFAOYSA-N 0.000 description 2
- KLUHZXMBIDAHSJ-UHFFFAOYSA-N 3-hydroxybutyl acetate Chemical compound CC(O)CCOC(C)=O KLUHZXMBIDAHSJ-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- HXDOZKJGKXYMEW-UHFFFAOYSA-N 4-ethylphenol Chemical compound CCC1=CC=C(O)C=C1 HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 2
- FUGKCSRLAQKUHG-UHFFFAOYSA-N 5-chloro-2-hydroxybenzaldehyde Chemical compound OC1=CC=C(Cl)C=C1C=O FUGKCSRLAQKUHG-UHFFFAOYSA-N 0.000 description 2
- UNYPADXZBSYXOL-UHFFFAOYSA-N 5-chloro-2-methoxy-3-phenoxypyridine Chemical compound COC1=NC=C(Cl)C=C1OC1=CC=CC=C1 UNYPADXZBSYXOL-UHFFFAOYSA-N 0.000 description 2
- WOSJQXCRYIYFKT-UHFFFAOYSA-N 5-ethyl-2-methoxypyridine Chemical compound CCC1=CC=C(OC)N=C1 WOSJQXCRYIYFKT-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021000 Hypoglycaemic coma Diseases 0.000 description 2
- 208000031773 Insulin resistance syndrome Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- 229940126033 PPAR agonist Drugs 0.000 description 2
- 108010044210 PPAR-beta Proteins 0.000 description 2
- 108091008767 PPARγ2 Proteins 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 241000183024 Populus tremula Species 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- UVMOXAFMJPNMNM-UHFFFAOYSA-N [2-methoxy-5-(trifluoromethyl)phenyl]-phenylmethanone Chemical compound COC1=CC=C(C(F)(F)F)C=C1C(=O)C1=CC=CC=C1 UVMOXAFMJPNMNM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229960001214 clofibrate Drugs 0.000 description 2
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- CFZHTKRLGAIXDR-UHFFFAOYSA-N cyclohexyl-(5-ethyl-2-hydroxyphenyl)methanone Chemical compound CCC1=CC=C(O)C(C(=O)C2CCCCC2)=C1 CFZHTKRLGAIXDR-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001030 gas--liquid chromatography Methods 0.000 description 2
- 229960003627 gemfibrozil Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000004460 liquid liquid chromatography Methods 0.000 description 2
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000003328 mesylation reaction Methods 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- RGEJEIMLIXNBCK-UHFFFAOYSA-N methyl 3-[4-[3-(2-benzoyl-4-ethylphenoxy)butoxy]-2-methylphenyl]propanoate Chemical compound C=1C=CC=CC=1C(=O)C1=CC(CC)=CC=C1OC(C)CCOC1=CC=C(CCC(=O)OC)C(C)=C1 RGEJEIMLIXNBCK-UHFFFAOYSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N methyl cyanide Natural products CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 210000002824 peroxisome Anatomy 0.000 description 2
- 229960003243 phenformin Drugs 0.000 description 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000002821 scintillation proximity assay Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- LOGPRZMQSREDOU-UHFFFAOYSA-N thiazolylphenol Natural products OC1=CC=CC=C1C1=NC=CS1 LOGPRZMQSREDOU-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 229960005371 tolbutamide Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
- 229960001641 troglitazone Drugs 0.000 description 2
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- XFQNWPYGEGCIMF-HCUGAJCMSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].[Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 XFQNWPYGEGCIMF-HCUGAJCMSA-N 0.000 description 1
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- RIFCEURUCJPMOQ-UHFFFAOYSA-N (2-hydroxy-5-methoxyphenyl)-phenylmethanone Chemical compound COC1=CC=C(O)C(C(=O)C=2C=CC=CC=2)=C1 RIFCEURUCJPMOQ-UHFFFAOYSA-N 0.000 description 1
- HGZHYRJRNRGSNH-UHFFFAOYSA-N (2-hydroxy-5-propan-2-ylphenyl)-phenylmethanone Chemical compound CC(C)C1=CC=C(O)C(C(=O)C=2C=CC=CC=2)=C1 HGZHYRJRNRGSNH-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- WNUWCYVVNPLAAZ-GFCCVEGCSA-N (3r)-3-(4-chloro-2-phenoxyphenoxy)butan-1-ol Chemical compound OCC[C@@H](C)OC1=CC=C(Cl)C=C1OC1=CC=CC=C1 WNUWCYVVNPLAAZ-GFCCVEGCSA-N 0.000 description 1
- FEFKJJOFHLOEGX-UHFFFAOYSA-N (5-ethyl-2-hydroxyphenyl)-phenylmethanone Chemical compound CCC1=CC=C(O)C(C(=O)C=2C=CC=CC=2)=C1 FEFKJJOFHLOEGX-UHFFFAOYSA-N 0.000 description 1
- RJACNUQXPIDDEV-UHFFFAOYSA-N (5-ethyl-2-methoxyphenyl)boronic acid Chemical compound CCC1=CC=C(OC)C(B(O)O)=C1 RJACNUQXPIDDEV-UHFFFAOYSA-N 0.000 description 1
- NIGDIYRSWPVNOR-UHFFFAOYSA-N (5-ethyl-2-methoxypyridin-3-yl)-phenylmethanol Chemical compound CCC1=CN=C(OC)C(C(O)C=2C=CC=CC=2)=C1 NIGDIYRSWPVNOR-UHFFFAOYSA-N 0.000 description 1
- RFEVDRKEBCPSTI-UHFFFAOYSA-N (5-ethyl-2-methoxypyridin-3-yl)-phenylmethanone Chemical compound CCC1=CN=C(OC)C(C(=O)C=2C=CC=CC=2)=C1 RFEVDRKEBCPSTI-UHFFFAOYSA-N 0.000 description 1
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 1
- PUPZLCDOIYMWBV-BYPYZUCNSA-N (S)-butane-1,3-diol Chemical compound C[C@H](O)CCO PUPZLCDOIYMWBV-BYPYZUCNSA-N 0.000 description 1
- USVVENVKYJZFMW-ONEGZZNKSA-N (e)-carboxyiminocarbamic acid Chemical compound OC(=O)\N=N\C(O)=O USVVENVKYJZFMW-ONEGZZNKSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- FUOSTELFLYZQCW-UHFFFAOYSA-N 1,2-oxazol-3-one Chemical compound OC=1C=CON=1 FUOSTELFLYZQCW-UHFFFAOYSA-N 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- IDXOBCGOYLVVDL-UHFFFAOYSA-N 1-(5-ethyl-2-hydroxyphenyl)-2-methylpropan-1-one Chemical compound CCC1=CC=C(O)C(C(=O)C(C)C)=C1 IDXOBCGOYLVVDL-UHFFFAOYSA-N 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- UAJRSHJHFRVGMG-UHFFFAOYSA-N 1-ethenyl-4-methoxybenzene Chemical compound COC1=CC=C(C=C)C=C1 UAJRSHJHFRVGMG-UHFFFAOYSA-N 0.000 description 1
- CFIPQRIPCRRISV-UHFFFAOYSA-N 1-methoxy-4-(trifluoromethyl)benzene Chemical compound COC1=CC=C(C(F)(F)F)C=C1 CFIPQRIPCRRISV-UHFFFAOYSA-N 0.000 description 1
- JULZQKLZSNOEEJ-UHFFFAOYSA-N 1-methoxy-4-propan-2-ylbenzene Chemical compound COC1=CC=C(C(C)C)C=C1 JULZQKLZSNOEEJ-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- FMRLPJIKHWZRDI-NRFANRHFSA-N 2-[2-methyl-4-[(3s)-3-(2-phenoxy-4-propan-2-ylphenoxy)butoxy]phenyl]sulfanylacetic acid Chemical compound C([C@H](C)OC=1C(=CC(=CC=1)C(C)C)OC=1C=CC=CC=1)COC1=CC=C(SCC(O)=O)C(C)=C1 FMRLPJIKHWZRDI-NRFANRHFSA-N 0.000 description 1
- YXIVQCBLNIYSBK-KRWDZBQOSA-N 2-[2-methyl-4-[(3s)-3-[3-phenoxy-5-(trifluoromethyl)pyridin-2-yl]oxybutoxy]phenyl]sulfanylacetic acid Chemical compound C([C@H](C)OC=1C(=CC(=CN=1)C(F)(F)F)OC=1C=CC=CC=1)COC1=CC=C(SCC(O)=O)C(C)=C1 YXIVQCBLNIYSBK-KRWDZBQOSA-N 0.000 description 1
- AZFDWOMVKDFBCO-GOSISDBHSA-N 2-[4-[(3r)-3-(2-benzoyl-4-chlorophenoxy)butoxy]-2-methylphenyl]sulfanylacetic acid Chemical compound C([C@@H](C)OC=1C(=CC(Cl)=CC=1)C(=O)C=1C=CC=CC=1)COC1=CC=C(SCC(O)=O)C(C)=C1 AZFDWOMVKDFBCO-GOSISDBHSA-N 0.000 description 1
- YJOQGAWMIQZDPW-OAQYLSRUSA-N 2-[4-[(3r)-3-(2-benzoyl-4-propan-2-ylphenoxy)butoxy]-2-methylphenyl]sulfanylacetic acid Chemical compound C([C@@H](C)OC=1C(=CC(=CC=1)C(C)C)C(=O)C=1C=CC=CC=1)COC1=CC=C(SCC(O)=O)C(C)=C1 YJOQGAWMIQZDPW-OAQYLSRUSA-N 0.000 description 1
- WQYNVBLIYAOYIQ-KRWDZBQOSA-N 2-[4-[(3s)-3-(3-benzoyl-4-chloropyridin-2-yl)oxybutoxy]-2-methylphenyl]sulfanylacetic acid Chemical compound C([C@H](C)OC=1C(=C(Cl)C=CN=1)C(=O)C=1C=CC=CC=1)COC1=CC=C(SCC(O)=O)C(C)=C1 WQYNVBLIYAOYIQ-KRWDZBQOSA-N 0.000 description 1
- RNBFSGDAVHUKJU-KRWDZBQOSA-N 2-[4-[(3s)-3-(5-chloro-3-phenoxypyridin-2-yl)oxybutoxy]-2-methylphenyl]sulfanylacetic acid Chemical compound C([C@H](C)OC=1C(=CC(Cl)=CN=1)OC=1C=CC=CC=1)COC1=CC=C(SCC(O)=O)C(C)=C1 RNBFSGDAVHUKJU-KRWDZBQOSA-N 0.000 description 1
- CMNXDUZTDHWDIP-KRWDZBQOSA-N 2-[4-[(3s)-3-[3-benzoyl-5-(trifluoromethyl)pyridin-2-yl]oxybutoxy]-2-methylphenyl]sulfanylacetic acid Chemical compound C([C@H](C)OC=1C(=CC(=CN=1)C(F)(F)F)C(=O)C=1C=CC=CC=1)COC1=CC=C(SCC(O)=O)C(C)=C1 CMNXDUZTDHWDIP-KRWDZBQOSA-N 0.000 description 1
- VBCZDVPPSIMFRM-ZENAZSQFSA-N 2-[4-[(3s)-3-[4-ethyl-2-(1,3-thiazol-2-yl)phenoxy]butoxy]-2-methylphenoxy]propanoic acid Chemical compound C([C@H](C)OC1=CC=C(C=C1C=1SC=CN=1)CC)COC1=CC=C(OC(C)C(O)=O)C(C)=C1 VBCZDVPPSIMFRM-ZENAZSQFSA-N 0.000 description 1
- BORVMWSAUYXLBN-UHFFFAOYSA-N 2-[4-[3-(2-benzoyl-4-ethylphenoxy)butoxy]-2-methylphenoxy]-2-methylpropanoic acid;triphenylphosphane Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1C(=O)C1=CC(CC)=CC=C1OC(C)CCOC1=CC=C(OC(C)(C)C(O)=O)C(C)=C1 BORVMWSAUYXLBN-UHFFFAOYSA-N 0.000 description 1
- KIRBLZZVBSYRGT-UHFFFAOYSA-N 2-[4-[3-(2-benzoyl-4-ethylphenoxy)butoxy]-2-methylphenoxy]acetic acid Chemical compound C=1C=CC=CC=1C(=O)C1=CC(CC)=CC=C1OC(C)CCOC1=CC=C(OCC(O)=O)C(C)=C1 KIRBLZZVBSYRGT-UHFFFAOYSA-N 0.000 description 1
- ZDYCLLIBBVXZPY-UHFFFAOYSA-N 2-[4-[3-(2-benzoyl-4-ethylphenoxy)butoxy]-2-methylphenyl]sulfanylacetic acid Chemical compound C=1C=CC=CC=1C(=O)C1=CC(CC)=CC=C1OC(C)CCOC1=CC=C(SCC(O)=O)C(C)=C1 ZDYCLLIBBVXZPY-UHFFFAOYSA-N 0.000 description 1
- GTAMAVCFXQXQCO-UHFFFAOYSA-N 2-[4-[3-(2-benzoyl-4-ethylphenoxy)butoxy]phenoxy]acetic acid Chemical compound C=1C=CC=CC=1C(=O)C1=CC(CC)=CC=C1OC(C)CCOC1=CC=C(OCC(O)=O)C=C1 GTAMAVCFXQXQCO-UHFFFAOYSA-N 0.000 description 1
- JUCOLUUNOVTCEP-UHFFFAOYSA-N 2-[4-[3-(2-benzoyl-4-ethylphenoxy)butyl]-2-methylphenoxy]acetic acid Chemical compound C=1C=CC=CC=1C(=O)C1=CC(CC)=CC=C1OC(C)CCC1=CC=C(OCC(O)=O)C(C)=C1 JUCOLUUNOVTCEP-UHFFFAOYSA-N 0.000 description 1
- HEVNIIFRNJBTBI-UHFFFAOYSA-N 2-[4-[3-(3-benzoyl-5-ethylpyridin-2-yl)oxybutoxy]-2-methylphenyl]sulfanylacetic acid Chemical compound C=1C=CC=CC=1C(=O)C1=CC(CC)=CN=C1OC(C)CCOC1=CC=C(SCC(O)=O)C(C)=C1 HEVNIIFRNJBTBI-UHFFFAOYSA-N 0.000 description 1
- TVGOUYKZMZPUKR-UHFFFAOYSA-N 2-[4-[3-[2-(cyclohexanecarbonyl)-4-ethylphenoxy]butoxy]phenoxy]-2-methylpropanoic acid Chemical compound C1CCCCC1C(=O)C1=CC(CC)=CC=C1OC(C)CCOC1=CC=C(OC(C)(C)C(O)=O)C=C1 TVGOUYKZMZPUKR-UHFFFAOYSA-N 0.000 description 1
- JECYUBVRTQDVAT-UHFFFAOYSA-N 2-acetylphenol Chemical class CC(=O)C1=CC=CC=C1O JECYUBVRTQDVAT-UHFFFAOYSA-N 0.000 description 1
- RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
- LGEUHIWKMYPPSN-UHFFFAOYSA-N 2-bromo-1-methoxy-4-propan-2-ylbenzene Chemical compound COC1=CC=C(C(C)C)C=C1Br LGEUHIWKMYPPSN-UHFFFAOYSA-N 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- ADWMKGCKKNULPN-UHFFFAOYSA-N 2-sulfinylpyrrole Chemical compound O=S=C1C=CC=N1 ADWMKGCKKNULPN-UHFFFAOYSA-N 0.000 description 1
- JRZBWRPPYOMOJE-UHFFFAOYSA-N 2-sulfonylpyrrole Chemical compound O=S(=O)=C1C=CC=N1 JRZBWRPPYOMOJE-UHFFFAOYSA-N 0.000 description 1
- WNUWCYVVNPLAAZ-UHFFFAOYSA-N 3-(4-chloro-2-phenoxyphenoxy)butan-1-ol Chemical compound OCCC(C)OC1=CC=C(Cl)C=C1OC1=CC=CC=C1 WNUWCYVVNPLAAZ-UHFFFAOYSA-N 0.000 description 1
- NVWBIIADUABHPY-UHFFFAOYSA-N 3-(4-chloro-2-phenoxyphenoxy)butyl acetate Chemical compound CC(=O)OCCC(C)OC1=CC=C(Cl)C=C1OC1=CC=CC=C1 NVWBIIADUABHPY-UHFFFAOYSA-N 0.000 description 1
- WOOIOHQAURURMV-QGZVFWFLSA-N 3-[2-chloro-4-[(3r)-3-(4-chloro-2-phenoxyphenoxy)butoxy]phenyl]propanoic acid Chemical compound C([C@@H](C)OC=1C(=CC(Cl)=CC=1)OC=1C=CC=CC=1)COC1=CC=C(CCC(O)=O)C(Cl)=C1 WOOIOHQAURURMV-QGZVFWFLSA-N 0.000 description 1
- KDJKQENXUFWMNB-SFHVURJKSA-N 3-[2-ethyl-4-[(3s)-3-[3-phenoxy-5-(trifluoromethyl)pyridin-2-yl]oxybutoxy]phenyl]propanoic acid Chemical compound C1=C(CCC(O)=O)C(CC)=CC(OCC[C@H](C)OC=2C(=CC(=CN=2)C(F)(F)F)OC=2C=CC=CC=2)=C1 KDJKQENXUFWMNB-SFHVURJKSA-N 0.000 description 1
- FXSCPCDLFUBORH-KRWDZBQOSA-N 3-[2-ethyl-4-[(3s)-3-[3-pyridin-3-yl-5-(trifluoromethyl)pyridin-2-yl]oxybutoxy]phenyl]propanoic acid Chemical compound C1=C(CCC(O)=O)C(CC)=CC(OCC[C@H](C)OC=2C(=CC(=CN=2)C(F)(F)F)C=2C=NC=CC=2)=C1 FXSCPCDLFUBORH-KRWDZBQOSA-N 0.000 description 1
- YGEPKBRPLQZNRA-LJQANCHMSA-N 3-[4-[(3r)-3-(2-benzoyl-4-chlorophenoxy)butoxy]-2-methylphenyl]propanoic acid Chemical compound C([C@@H](C)OC=1C(=CC(Cl)=CC=1)C(=O)C=1C=CC=CC=1)COC1=CC=C(CCC(O)=O)C(C)=C1 YGEPKBRPLQZNRA-LJQANCHMSA-N 0.000 description 1
- MDUAUPGOROLGSO-OAQYLSRUSA-N 3-[4-[(3r)-3-(2-benzoyl-4-cyclopropylphenoxy)butoxy]-2-methylphenyl]propanoic acid Chemical compound C([C@@H](C)OC=1C(=CC(=CC=1)C1CC1)C(=O)C=1C=CC=CC=1)COC1=CC=C(CCC(O)=O)C(C)=C1 MDUAUPGOROLGSO-OAQYLSRUSA-N 0.000 description 1
- CIPGEDLLCCHFDI-LJQANCHMSA-N 3-[4-[(3r)-3-(4-chloro-2-phenoxyphenoxy)butoxy]-2-ethylphenyl]propanoic acid Chemical compound C1=C(CCC(O)=O)C(CC)=CC(OCC[C@@H](C)OC=2C(=CC(Cl)=CC=2)OC=2C=CC=CC=2)=C1 CIPGEDLLCCHFDI-LJQANCHMSA-N 0.000 description 1
- WXCQOBJBCVSXBR-QGZVFWFLSA-N 3-[4-[(3r)-3-(4-chloro-2-phenoxyphenoxy)butoxy]-2-fluorophenyl]propanoic acid Chemical compound C([C@@H](C)OC=1C(=CC(Cl)=CC=1)OC=1C=CC=CC=1)COC1=CC=C(CCC(O)=O)C(F)=C1 WXCQOBJBCVSXBR-QGZVFWFLSA-N 0.000 description 1
- NNGKANIMGUGHQC-GOSISDBHSA-N 3-[4-[(3r)-3-(4-chloro-2-phenoxyphenoxy)butoxy]phenyl]propanoic acid Chemical compound C([C@@H](C)OC=1C(=CC(Cl)=CC=1)OC=1C=CC=CC=1)COC1=CC=C(CCC(O)=O)C=C1 NNGKANIMGUGHQC-GOSISDBHSA-N 0.000 description 1
- FOHOYQFJHBMCTN-JOCHJYFZSA-N 3-[4-[(3r)-3-[4-ethyl-2-(n-methoxy-c-phenylcarbonimidoyl)phenoxy]butoxy]-2-methylphenyl]propanoic acid Chemical compound C([C@@H](C)OC1=CC=C(C=C1C(=NOC)C=1C=CC=CC=1)CC)COC1=CC=C(CCC(O)=O)C(C)=C1 FOHOYQFJHBMCTN-JOCHJYFZSA-N 0.000 description 1
- SRXCBLVVXYOMAI-QYWNIODHSA-N 3-[4-[(3r)-3-[4-ethyl-2-[hydroxy(phenyl)methyl]phenoxy]butoxy]-2-methylphenyl]propanoic acid Chemical compound C([C@@H](C)OC1=CC=C(C=C1C(O)C=1C=CC=CC=1)CC)COC1=CC=C(CCC(O)=O)C(C)=C1 SRXCBLVVXYOMAI-QYWNIODHSA-N 0.000 description 1
- GILNREMWBDGIQX-IBGZPJMESA-N 3-[4-[(3s)-3-(4-ethyl-2-thiophen-2-ylphenoxy)butoxy]-2-methylphenyl]propanoic acid Chemical compound C([C@H](C)OC1=CC=C(C=C1C=1SC=CC=1)CC)COC1=CC=C(CCC(O)=O)C(C)=C1 GILNREMWBDGIQX-IBGZPJMESA-N 0.000 description 1
- TXQWNSUACRVUHV-SFHVURJKSA-N 3-[4-[(3s)-3-(5-chloro-3-phenoxypyridin-2-yl)oxybutoxy]-2-methylphenyl]propanoic acid Chemical compound C([C@H](C)OC=1C(=CC(Cl)=CN=1)OC=1C=CC=CC=1)COC1=CC=C(CCC(O)=O)C(C)=C1 TXQWNSUACRVUHV-SFHVURJKSA-N 0.000 description 1
- ONHBOWNRMGRYNP-UHFFFAOYSA-N 3-[4-[3-(2-benzoyl-4-ethylphenoxy)butoxy]-2-methylphenyl]propanoic acid Chemical compound C=1C=CC=CC=1C(=O)C1=CC(CC)=CC=C1OC(C)CCOC1=CC=C(CCC(O)=O)C(C)=C1 ONHBOWNRMGRYNP-UHFFFAOYSA-N 0.000 description 1
- FNMZACADBUGSRS-UHFFFAOYSA-N 3-[4-[3-(2-benzoyl-4-ethylphenoxy)butoxy]phenyl]-2-methoxypropanoic acid Chemical compound C=1C=CC=CC=1C(=O)C1=CC(CC)=CC=C1OC(C)CCOC1=CC=C(CC(OC)C(O)=O)C=C1 FNMZACADBUGSRS-UHFFFAOYSA-N 0.000 description 1
- OXKYUCWENHOHEL-UHFFFAOYSA-N 3-[4-[3-(2-benzoyl-4-propan-2-ylphenoxy)butoxy]-2-methylphenyl]propanoic acid Chemical compound C=1C=CC=CC=1C(=O)C1=CC(C(C)C)=CC=C1OC(C)CCOC1=CC=C(CCC(O)=O)C(C)=C1 OXKYUCWENHOHEL-UHFFFAOYSA-N 0.000 description 1
- MLAIYRUTWHHMGW-UHFFFAOYSA-N 3-[4-[3-[2-(cyclopentanecarbonyl)-4-ethylphenoxy]butoxy]-2-methylphenyl]propanoic acid Chemical compound C1CCCC1C(=O)C1=CC(CC)=CC=C1OC(C)CCOC1=CC=C(CCC(O)=O)C(C)=C1 MLAIYRUTWHHMGW-UHFFFAOYSA-N 0.000 description 1
- AGXUQLYVKBIAKO-UHFFFAOYSA-N 3-[4-[3-[2-benzoyl-4-(trifluoromethyl)phenoxy]butoxy]-2-methylphenyl]propanoic acid Chemical compound C=1C=C(C(F)(F)F)C=C(C(=O)C=2C=CC=CC=2)C=1OC(C)CCOC1=CC=C(CCC(O)=O)C(C)=C1 AGXUQLYVKBIAKO-UHFFFAOYSA-N 0.000 description 1
- AYEVELLBDURPJW-UHFFFAOYSA-N 3-bromo-5-chloro-2-methoxypyridine Chemical compound COC1=NC=C(Cl)C=C1Br AYEVELLBDURPJW-UHFFFAOYSA-N 0.000 description 1
- WYZFEDDESWMESG-UHFFFAOYSA-N 3-pyridin-3-yl-5-(trifluoromethyl)-1h-pyridin-2-one Chemical compound OC1=NC=C(C(F)(F)F)C=C1C1=CC=CN=C1 WYZFEDDESWMESG-UHFFFAOYSA-N 0.000 description 1
- IYTJRMRETHPZAC-UHFFFAOYSA-N 4,4-dibenzylpiperidine Chemical compound C1CNCCC1(CC=1C=CC=CC=1)CC1=CC=CC=C1 IYTJRMRETHPZAC-UHFFFAOYSA-N 0.000 description 1
- RMKPGFLAGOPHSI-UHFFFAOYSA-N 4-chloro-2-(1,3-thiazol-4-yl)phenol Chemical compound OC1=CC=C(Cl)C=C1C1=CSC=N1 RMKPGFLAGOPHSI-UHFFFAOYSA-N 0.000 description 1
- PUJRASZLZCXERM-UHFFFAOYSA-N 4-chloro-2-phenoxyphenol Chemical compound OC1=CC=C(Cl)C=C1OC1=CC=CC=C1 PUJRASZLZCXERM-UHFFFAOYSA-N 0.000 description 1
- WNKVEWQBUBLYOL-UHFFFAOYSA-N 4-chloro-2-pyridin-2-ylphenol Chemical compound OC1=CC=C(Cl)C=C1C1=CC=CC=N1 WNKVEWQBUBLYOL-UHFFFAOYSA-N 0.000 description 1
- LIBACFQLOSQOKX-UHFFFAOYSA-N 4-ethyl-1-methoxy-2-phenylbenzene Chemical group CCC1=CC=C(OC)C(C=2C=CC=CC=2)=C1 LIBACFQLOSQOKX-UHFFFAOYSA-N 0.000 description 1
- SIKLITBBFLJHMK-UHFFFAOYSA-N 4-ethyl-2-(1,3-oxazol-2-yl)phenol Chemical compound CCC1=CC=C(O)C(C=2OC=CN=2)=C1 SIKLITBBFLJHMK-UHFFFAOYSA-N 0.000 description 1
- DRPQTEDTSZRTKB-UHFFFAOYSA-N 4-ethyl-2-(1,3-oxazol-4-yl)phenol Chemical compound CCC1=CC=C(O)C(C=2N=COC=2)=C1 DRPQTEDTSZRTKB-UHFFFAOYSA-N 0.000 description 1
- ZCQAAEOOEBWVEF-UHFFFAOYSA-N 4-ethyl-2-(1,3-thiazol-4-yl)phenol Chemical compound CCC1=CC=C(O)C(C=2N=CSC=2)=C1 ZCQAAEOOEBWVEF-UHFFFAOYSA-N 0.000 description 1
- LOHOSTXTWMYUMQ-UHFFFAOYSA-N 4-ethyl-2-(1h-pyrrol-2-yl)phenol Chemical compound CCC1=CC=C(O)C(C=2NC=CC=2)=C1 LOHOSTXTWMYUMQ-UHFFFAOYSA-N 0.000 description 1
- FBLJCNYGHROMHF-UHFFFAOYSA-N 4-ethyl-2-(furan-2-yl)phenol Chemical compound CCC1=CC=C(O)C(C=2OC=CC=2)=C1 FBLJCNYGHROMHF-UHFFFAOYSA-N 0.000 description 1
- WAWIDYDFJXHGDQ-UHFFFAOYSA-N 4-ethyl-2-phenylphenol Chemical compound CCC1=CC=C(O)C(C=2C=CC=CC=2)=C1 WAWIDYDFJXHGDQ-UHFFFAOYSA-N 0.000 description 1
- ISVVTOVVHINZNT-UHFFFAOYSA-N 4-ethyl-2-pyridin-2-ylphenol Chemical compound CCC1=CC=C(O)C(C=2N=CC=CC=2)=C1 ISVVTOVVHINZNT-UHFFFAOYSA-N 0.000 description 1
- PEWUGEIPSFNYLM-UHFFFAOYSA-N 4-ethyl-2-pyridin-3-ylphenol Chemical compound CCC1=CC=C(O)C(C=2C=NC=CC=2)=C1 PEWUGEIPSFNYLM-UHFFFAOYSA-N 0.000 description 1
- OIDHZLYKTKBVCF-UHFFFAOYSA-N 4-ethyl-2-pyridin-4-ylphenol Chemical compound CCC1=CC=C(O)C(C=2C=CN=CC=2)=C1 OIDHZLYKTKBVCF-UHFFFAOYSA-N 0.000 description 1
- YJZNHKCIYYKIQH-UHFFFAOYSA-N 4-ethyl-2-thiophen-3-ylphenol Chemical compound CCC1=CC=C(O)C(C2=CSC=C2)=C1 YJZNHKCIYYKIQH-UHFFFAOYSA-N 0.000 description 1
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 1
- XADICJHFELMBGX-UHFFFAOYSA-N 5-bromo-2-methoxypyridine Chemical compound COC1=CC=C(Br)C=N1 XADICJHFELMBGX-UHFFFAOYSA-N 0.000 description 1
- NPYYXUYLIHZYOU-UHFFFAOYSA-N 5-chloro-2-methoxypyridine Chemical compound COC1=CC=C(Cl)C=N1 NPYYXUYLIHZYOU-UHFFFAOYSA-N 0.000 description 1
- VIYPGFYPRQILNO-UHFFFAOYSA-N 5-chloro-3-pyridin-3-yl-1h-pyridin-2-one Chemical compound OC1=NC=C(Cl)C=C1C1=CC=CN=C1 VIYPGFYPRQILNO-UHFFFAOYSA-N 0.000 description 1
- XSTCLZHMZASDDK-UHFFFAOYSA-N 5-ethyl-2-hydroxybenzaldehyde Chemical compound CCC1=CC=C(O)C(C=O)=C1 XSTCLZHMZASDDK-UHFFFAOYSA-N 0.000 description 1
- QNNOMPQMNMUYNG-UHFFFAOYSA-N 6-methyl-2-phenoxypyridin-3-ol Chemical compound CC1=CC=C(O)C(OC=2C=CC=CC=2)=N1 QNNOMPQMNMUYNG-UHFFFAOYSA-N 0.000 description 1
- 101150071783 APOA1 gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- PXZRFKGLBCZTQZ-UHFFFAOYSA-L C([O-])([O-])=O.[Cs+].C(C)C=1C=CC(=C(C=1)C1=CC=CC=C1)OC(CCOC1=CC(=C(C=C1)CCC(=O)O)C)C.[Cs+] Chemical compound C([O-])([O-])=O.[Cs+].C(C)C=1C=CC(=C(C=1)C1=CC=CC=C1)OC(CCOC1=CC(=C(C=C1)CCC(=O)O)C)C.[Cs+] PXZRFKGLBCZTQZ-UHFFFAOYSA-L 0.000 description 1
- CXJSQHQQROBQEI-UHFFFAOYSA-L C([O-])([O-])=O.[Cs+].C(C1=CC=CC=C1)(=O)C1=C(OC(CCC2=CC(=C(OCC(=O)O)C=C2)C)C)C=CC(=C1)CC.[Cs+] Chemical compound C([O-])([O-])=O.[Cs+].C(C1=CC=CC=C1)(=O)C1=C(OC(CCC2=CC(=C(OCC(=O)O)C=C2)C)C)C=CC(=C1)CC.[Cs+] CXJSQHQQROBQEI-UHFFFAOYSA-L 0.000 description 1
- RSWCGOYXYLJUAT-UHFFFAOYSA-L C([O-])([O-])=O.[Cs+].C(C1=CC=CC=C1)(=O)C1=C(OC(CCOC2=CC(=C(C=C2)CCC(=O)O)C)C)C=CC(=C1)C(C)C.[Cs+] Chemical compound C([O-])([O-])=O.[Cs+].C(C1=CC=CC=C1)(=O)C1=C(OC(CCOC2=CC(=C(C=C2)CCC(=O)O)C)C)C=CC(=C1)C(C)C.[Cs+] RSWCGOYXYLJUAT-UHFFFAOYSA-L 0.000 description 1
- BSHPJTMFNOXFGZ-UHFFFAOYSA-L C([O-])([O-])=O.[Cs+].C(C1=CC=CC=C1)(=O)C1=C(OC(CCOC2=CC(=C(C=C2)CCC(=O)O)C)C)C=CC(=C1)C(F)(F)F.[Cs+] Chemical compound C([O-])([O-])=O.[Cs+].C(C1=CC=CC=C1)(=O)C1=C(OC(CCOC2=CC(=C(C=C2)CCC(=O)O)C)C)C=CC(=C1)C(F)(F)F.[Cs+] BSHPJTMFNOXFGZ-UHFFFAOYSA-L 0.000 description 1
- BKTYCJOMVSHZLH-UHFFFAOYSA-L C([O-])([O-])=O.[Cs+].C(C1=CC=CC=C1)(=O)C=1C(=NC=C(C=1)CC)OC(CCOC1=CC(=C(C=C1)CCC(=O)O)C)C.[Cs+] Chemical compound C([O-])([O-])=O.[Cs+].C(C1=CC=CC=C1)(=O)C=1C(=NC=C(C=1)CC)OC(CCOC1=CC(=C(C=C1)CCC(=O)O)C)C.[Cs+] BKTYCJOMVSHZLH-UHFFFAOYSA-L 0.000 description 1
- DUGXRDROHPEZCB-LPECGTQYSA-L C([O-])([O-])=O.[K+].ClC=1C=C(C(=NC1)O[C@H](CCOC1=CC(=C(C=C1)CCC(=O)O)C)C)OC1=CC=CC=C1.[K+] Chemical compound C([O-])([O-])=O.[K+].ClC=1C=C(C(=NC1)O[C@H](CCOC1=CC(=C(C=C1)CCC(=O)O)C)C)OC1=CC=CC=C1.[K+] DUGXRDROHPEZCB-LPECGTQYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CFHNRSPMHACNBU-UHFFFAOYSA-N Cl.C(CC)(=O)O.NO Chemical compound Cl.C(CC)(=O)O.NO CFHNRSPMHACNBU-UHFFFAOYSA-N 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 101100321992 Drosophila melanogaster ABCD gene Proteins 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101001093899 Homo sapiens Retinoic acid receptor RXR-alpha Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 229940077672 Ileal bile acid transport inhibitor Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101150046735 LEPR gene Proteins 0.000 description 1
- 101150063827 LEPROT gene Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091008768 PPARγ1 Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 101710117029 Peroxisome proliferator-activated receptor delta Proteins 0.000 description 1
- 229940122054 Peroxisome proliferator-activated receptor delta agonist Drugs 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100035178 Retinoic acid receptor RXR-alpha Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000006619 Stille reaction Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- UGMVUKKGPNPZSS-LLVKDONJSA-N [(3R)-3-(4-methylphenyl)sulfonyloxybutyl] acetate Chemical compound CC(=O)OCC[C@@H](C)OS(=O)(=O)C1=CC=C(C)C=C1 UGMVUKKGPNPZSS-LLVKDONJSA-N 0.000 description 1
- NDGNGQHXEVGWAB-CYBMUJFWSA-N [(3r)-3-(4-chloro-2-phenoxyphenoxy)butyl] methanesulfonate Chemical compound CS(=O)(=O)OCC[C@@H](C)OC1=CC=C(Cl)C=C1OC1=CC=CC=C1 NDGNGQHXEVGWAB-CYBMUJFWSA-N 0.000 description 1
- UGMVUKKGPNPZSS-NSHDSACASA-N [(3s)-3-(4-methylphenyl)sulfonyloxybutyl] acetate Chemical compound CC(=O)OCC[C@H](C)OS(=O)(=O)C1=CC=C(C)C=C1 UGMVUKKGPNPZSS-NSHDSACASA-N 0.000 description 1
- KLUHZXMBIDAHSJ-YFKPBYRVSA-N [(3s)-3-hydroxybutyl] acetate Chemical compound C[C@H](O)CCOC(C)=O KLUHZXMBIDAHSJ-YFKPBYRVSA-N 0.000 description 1
- PXAUGDBEWPHTOA-FBWDVMFLSA-N [Na].C(C)C1=CC(=C(O[C@@H](CCOC2=CC(=C(C=C2)CCC(=O)O)C)C)C=C1)C(C1=CC=CC=C1)O Chemical compound [Na].C(C)C1=CC(=C(O[C@@H](CCOC2=CC(=C(C=C2)CCC(=O)O)C)C)C=C1)C(C1=CC=CC=C1)O PXAUGDBEWPHTOA-FBWDVMFLSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001466 acetohexamide Drugs 0.000 description 1
- VGZSUPCWNCWDAN-UHFFFAOYSA-N acetohexamide Chemical compound C1=CC(C(=O)C)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 VGZSUPCWNCWDAN-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- LSTUARSWANEFBZ-UHFFFAOYSA-N cyclopentyl-(5-ethyl-2-hydroxyphenyl)methanone Chemical compound CCC1=CC=C(O)C(C(=O)C2CCCC2)=C1 LSTUARSWANEFBZ-UHFFFAOYSA-N 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 108700023159 delta Opioid Receptors Proteins 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- FHFCSCOISOJMCS-RFCADEKQSA-L dicesium 3-[4-[(3R)-3-(2-benzoyl-4-cyclopropylphenoxy)butoxy]-2-methylphenyl]propanoic acid carbonate Chemical compound C([O-])([O-])=O.[Cs+].C(C1=CC=CC=C1)(=O)C1=C(O[C@@H](CCOC2=CC(=C(C=C2)CCC(=O)O)C)C)C=CC(=C1)C1CC1.[Cs+] FHFCSCOISOJMCS-RFCADEKQSA-L 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- AHJQBNVBFJGSMO-UHFFFAOYSA-N ethyl 2-(2-methyl-4-sulfanylphenoxy)acetate Chemical compound CCOC(=O)COC1=CC=C(S)C=C1C AHJQBNVBFJGSMO-UHFFFAOYSA-N 0.000 description 1
- PBNAWTJZYVLBIP-UHFFFAOYSA-N ethyl 2-(3-hydroxyphenoxy)-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)OC1=CC=CC(O)=C1 PBNAWTJZYVLBIP-UHFFFAOYSA-N 0.000 description 1
- ZLLUDQCJBVEZTQ-UHFFFAOYSA-N ethyl 2-(4-hydroxy-2-methylphenoxy)-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(O)C=C1C ZLLUDQCJBVEZTQ-UHFFFAOYSA-N 0.000 description 1
- PBQNKBWWOXOAOE-UHFFFAOYSA-N ethyl 2-(4-hydroxyphenoxy)acetate Chemical compound CCOC(=O)COC1=CC=C(O)C=C1 PBQNKBWWOXOAOE-UHFFFAOYSA-N 0.000 description 1
- CXARMLNFNKNENA-QHCPKHFHSA-N ethyl 2-[2-methyl-4-[(3s)-3-(2-phenoxy-4-propan-2-ylphenoxy)butoxy]phenyl]sulfanylacetate Chemical compound C1=C(C)C(SCC(=O)OCC)=CC=C1OCC[C@H](C)OC1=CC=C(C(C)C)C=C1OC1=CC=CC=C1 CXARMLNFNKNENA-QHCPKHFHSA-N 0.000 description 1
- FEBXESXPJYYWRG-IBGZPJMESA-N ethyl 2-[2-methyl-4-[(3s)-3-[3-phenoxy-5-(trifluoromethyl)pyridin-2-yl]oxybutoxy]phenyl]sulfanylacetate Chemical compound C1=C(C)C(SCC(=O)OCC)=CC=C1OCC[C@H](C)OC1=NC=C(C(F)(F)F)C=C1OC1=CC=CC=C1 FEBXESXPJYYWRG-IBGZPJMESA-N 0.000 description 1
- HJVWYMKGELTYEV-UHFFFAOYSA-N ethyl 2-[3-[3-(2-benzoyl-4-ethylphenoxy)butoxy]phenoxy]-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)OC1=CC=CC(OCCC(C)OC=2C(=CC(CC)=CC=2)C(=O)C=2C=CC=CC=2)=C1 HJVWYMKGELTYEV-UHFFFAOYSA-N 0.000 description 1
- CHRJZSZAKSHURV-HXUWFJFHSA-N ethyl 2-[4-[(3r)-3-(2-benzoyl-4-chlorophenoxy)butoxy]-2-methylphenyl]sulfanylacetate Chemical compound C1=C(C)C(SCC(=O)OCC)=CC=C1OCC[C@@H](C)OC1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 CHRJZSZAKSHURV-HXUWFJFHSA-N 0.000 description 1
- YGZFMGSYNBGYIX-HSZRJFAPSA-N ethyl 2-[4-[(3r)-3-(2-benzoyl-4-propan-2-ylphenoxy)butoxy]-2-methylphenyl]sulfanylacetate Chemical compound C1=C(C)C(SCC(=O)OCC)=CC=C1OCC[C@@H](C)OC1=CC=C(C(C)C)C=C1C(=O)C1=CC=CC=C1 YGZFMGSYNBGYIX-HSZRJFAPSA-N 0.000 description 1
- JFSYUXXIZGSBPM-IBGZPJMESA-N ethyl 2-[4-[(3s)-3-(3-benzoyl-4-chloropyridin-2-yl)oxybutoxy]-2-methylphenyl]sulfanylacetate Chemical compound C1=C(C)C(SCC(=O)OCC)=CC=C1OCC[C@H](C)OC1=NC=CC(Cl)=C1C(=O)C1=CC=CC=C1 JFSYUXXIZGSBPM-IBGZPJMESA-N 0.000 description 1
- DRGRZOJKISBJDJ-IBGZPJMESA-N ethyl 2-[4-[(3s)-3-(5-chloro-3-phenoxypyridin-2-yl)oxybutoxy]-2-methylphenyl]sulfanylacetate Chemical compound C1=C(C)C(SCC(=O)OCC)=CC=C1OCC[C@H](C)OC1=NC=C(Cl)C=C1OC1=CC=CC=C1 DRGRZOJKISBJDJ-IBGZPJMESA-N 0.000 description 1
- ZGQXOCMOHSXLRX-IBGZPJMESA-N ethyl 2-[4-[(3s)-3-[3-benzoyl-5-(trifluoromethyl)pyridin-2-yl]oxybutoxy]-2-methylphenyl]sulfanylacetate Chemical compound C1=C(C)C(SCC(=O)OCC)=CC=C1OCC[C@H](C)OC1=NC=C(C(F)(F)F)C=C1C(=O)C1=CC=CC=C1 ZGQXOCMOHSXLRX-IBGZPJMESA-N 0.000 description 1
- PLMGJOYQSOLNOX-UHFFFAOYSA-N ethyl 2-[4-[3-(2-benzoyl-4-ethylphenoxy)butoxy]-2-methylphenyl]sulfanylacetate Chemical compound C1=C(C)C(SCC(=O)OCC)=CC=C1OCCC(C)OC1=CC=C(CC)C=C1C(=O)C1=CC=CC=C1 PLMGJOYQSOLNOX-UHFFFAOYSA-N 0.000 description 1
- PVEHSSNXLIISAX-UHFFFAOYSA-N ethyl 2-[4-[3-(2-benzoyl-4-ethylphenoxy)butoxy]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OCC)=CC=C1OCCC(C)OC1=CC=C(CC)C=C1C(=O)C1=CC=CC=C1 PVEHSSNXLIISAX-UHFFFAOYSA-N 0.000 description 1
- ROIOBYDOKZBIJY-UHFFFAOYSA-N ethyl 2-[4-[3-(2-benzoyl-4-ethylphenoxy)butyl]-2-methylphenoxy]acetate Chemical compound C1=C(C)C(OCC(=O)OCC)=CC=C1CCC(C)OC1=CC=C(CC)C=C1C(=O)C1=CC=CC=C1 ROIOBYDOKZBIJY-UHFFFAOYSA-N 0.000 description 1
- UBIASJWHPPAOKN-UHFFFAOYSA-N ethyl 2-[4-[3-(3-benzoyl-5-ethylpyridin-2-yl)oxybutoxy]-2-methylphenyl]sulfanylacetate Chemical compound C1=C(C)C(SCC(=O)OCC)=CC=C1OCCC(C)OC1=NC=C(CC)C=C1C(=O)C1=CC=CC=C1 UBIASJWHPPAOKN-UHFFFAOYSA-N 0.000 description 1
- UQUKSQVBUPLWPZ-UHFFFAOYSA-N ethyl 3-(2-chloro-4-hydroxyphenyl)propanoate Chemical compound CCOC(=O)CCC1=CC=C(O)C=C1Cl UQUKSQVBUPLWPZ-UHFFFAOYSA-N 0.000 description 1
- DQRGLCLEGSZGSN-UHFFFAOYSA-N ethyl 3-(2-ethyl-4-hydroxyphenyl)propanoate Chemical compound CCOC(=O)CCC1=CC=C(O)C=C1CC DQRGLCLEGSZGSN-UHFFFAOYSA-N 0.000 description 1
- ZIUFSWWLZLUAND-UHFFFAOYSA-N ethyl 3-(2-fluoro-4-hydroxyphenyl)propanoate Chemical compound CCOC(=O)CCC1=CC=C(O)C=C1F ZIUFSWWLZLUAND-UHFFFAOYSA-N 0.000 description 1
- XATGNBGJUVMMHM-UHFFFAOYSA-N ethyl 3-(3-hydroxyphenyl)-2-methoxypropanoate Chemical compound CCOC(=O)C(OC)CC1=CC=CC(O)=C1 XATGNBGJUVMMHM-UHFFFAOYSA-N 0.000 description 1
- SFTYDROGLAWTKI-UHFFFAOYSA-N ethyl 3-(4-hydroxyphenyl)-2-methoxypropanoate Chemical compound CCOC(=O)C(OC)CC1=CC=C(O)C=C1 SFTYDROGLAWTKI-UHFFFAOYSA-N 0.000 description 1
- KRPBANIWNOSKSV-FQEVSTJZSA-N ethyl 3-[2-ethyl-4-[(3s)-3-[3-phenoxy-5-(trifluoromethyl)pyridin-2-yl]oxybutoxy]phenyl]propanoate Chemical compound C1=C(CC)C(CCC(=O)OCC)=CC=C1OCC[C@H](C)OC1=NC=C(C(F)(F)F)C=C1OC1=CC=CC=C1 KRPBANIWNOSKSV-FQEVSTJZSA-N 0.000 description 1
- VUJUGESVMFQPAI-IBGZPJMESA-N ethyl 3-[2-ethyl-4-[(3s)-3-[3-pyridin-3-yl-5-(trifluoromethyl)pyridin-2-yl]oxybutoxy]phenyl]propanoate Chemical compound C1=C(CC)C(CCC(=O)OCC)=CC=C1OCC[C@H](C)OC1=NC=C(C(F)(F)F)C=C1C1=CC=CN=C1 VUJUGESVMFQPAI-IBGZPJMESA-N 0.000 description 1
- QLNFVBSJXOTJLX-UHFFFAOYSA-N ethyl 3-[4-[3-(2-benzoyl-4-ethylphenoxy)butoxy]phenyl]-2-methoxypropanoate Chemical compound C1=CC(CC(C(=O)OCC)OC)=CC=C1OCCC(C)OC1=CC=C(CC)C=C1C(=O)C1=CC=CC=C1 QLNFVBSJXOTJLX-UHFFFAOYSA-N 0.000 description 1
- VTKOVHQHWGDBOJ-UHFFFAOYSA-N ethyl 4-(4-hydroxy-2-methylphenyl)butanoate Chemical compound CCOC(=O)CCCC1=CC=C(O)C=C1C VTKOVHQHWGDBOJ-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 229960003501 etofibrate Drugs 0.000 description 1
- XXRVYAFBUDSLJX-UHFFFAOYSA-N etofibrate Chemical compound C=1C=CN=CC=1C(=O)OCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 XXRVYAFBUDSLJX-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 229960000701 fenofibric acid Drugs 0.000 description 1
- MQOBSOSZFYZQOK-UHFFFAOYSA-N fenofibric acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C(=O)C1=CC=C(Cl)C=C1 MQOBSOSZFYZQOK-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229950008446 melinamide Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- PLJUKCNTHGWZJP-UHFFFAOYSA-N methyl 2-(4-hydroxy-2-methylphenyl)propanoate Chemical compound COC(C(C)C1=C(C=C(C=C1)O)C)=O PLJUKCNTHGWZJP-UHFFFAOYSA-N 0.000 description 1
- DZIQUZJSNSZOCH-UHFFFAOYSA-N methyl 2-phenylpropanoate Chemical compound COC(=O)C(C)C1=CC=CC=C1 DZIQUZJSNSZOCH-UHFFFAOYSA-N 0.000 description 1
- FBACHQIYVSMFOM-UHFFFAOYSA-N methyl 3-[2-methyl-4-(3-methylsulfonyloxypropoxy)phenyl]propanoate Chemical compound COC(=O)CCC1=CC=C(OCCCOS(C)(=O)=O)C=C1C FBACHQIYVSMFOM-UHFFFAOYSA-N 0.000 description 1
- AWUWOYBSPHWQFL-NRFANRHFSA-N methyl 3-[2-methyl-4-[(3s)-3-(6-methyl-2-phenoxypyridin-3-yl)oxybutoxy]phenyl]propanoate Chemical compound C1=C(C)C(CCC(=O)OC)=CC=C1OCC[C@H](C)OC1=CC=C(C)N=C1OC1=CC=CC=C1 AWUWOYBSPHWQFL-NRFANRHFSA-N 0.000 description 1
- XADKKCGBOSYVQA-SFHVURJKSA-N methyl 3-[2-methyl-4-[(3s)-3-[3-pyridin-3-yl-5-(trifluoromethyl)pyridin-2-yl]oxybutoxy]phenyl]propanoate Chemical compound C1=C(C)C(CCC(=O)OC)=CC=C1OCC[C@H](C)OC1=NC=C(C(F)(F)F)C=C1C1=CC=CN=C1 XADKKCGBOSYVQA-SFHVURJKSA-N 0.000 description 1
- RGEJEIMLIXNBCK-JOCHJYFZSA-N methyl 3-[4-[(3r)-3-(2-benzoyl-4-ethylphenoxy)butoxy]-2-methylphenyl]propanoate Chemical compound C([C@@H](C)OC1=CC=C(C=C1C(=O)C=1C=CC=CC=1)CC)COC1=CC=C(CCC(=O)OC)C(C)=C1 RGEJEIMLIXNBCK-JOCHJYFZSA-N 0.000 description 1
- FLZXSDRVXQIQBS-VWRCBCJMSA-N methyl 3-[4-[(3r)-3-[4-ethyl-2-[hydroxy(phenyl)methyl]phenoxy]butoxy]-2-methylphenyl]propanoate Chemical compound C([C@@H](C)OC1=CC=C(C=C1C(O)C=1C=CC=CC=1)CC)COC1=CC=C(CCC(=O)OC)C(C)=C1 FLZXSDRVXQIQBS-VWRCBCJMSA-N 0.000 description 1
- GFNHMMKLLKALQR-IBGZPJMESA-N methyl 3-[4-[(3s)-3-(3-benzoyl-5-chloropyridin-2-yl)oxybutoxy]-2-methylphenyl]propanoate Chemical compound C1=C(C)C(CCC(=O)OC)=CC=C1OCC[C@H](C)OC1=NC=C(Cl)C=C1C(=O)C1=CC=CC=C1 GFNHMMKLLKALQR-IBGZPJMESA-N 0.000 description 1
- NMBPCMGSOACYIN-IBGZPJMESA-N methyl 3-[4-[(3s)-3-(4-chloro-2-pyridin-2-ylphenoxy)butoxy]-2-methylphenyl]propanoate Chemical compound C1=C(C)C(CCC(=O)OC)=CC=C1OCC[C@H](C)OC1=CC=C(Cl)C=C1C1=CC=CC=N1 NMBPCMGSOACYIN-IBGZPJMESA-N 0.000 description 1
- HBSOKXDDNQVZHO-NRFANRHFSA-N methyl 3-[4-[(3s)-3-(4-ethyl-2-pyridin-2-ylphenoxy)butoxy]-2-methylphenyl]propanoate Chemical compound C([C@H](C)OC1=CC=C(C=C1C=1N=CC=CC=1)CC)COC1=CC=C(CCC(=O)OC)C(C)=C1 HBSOKXDDNQVZHO-NRFANRHFSA-N 0.000 description 1
- OYBMNTODSPCODZ-SFHVURJKSA-N methyl 3-[4-[(3s)-3-(5-chloro-3-pyridin-3-ylpyridin-2-yl)oxybutoxy]-2-methylphenyl]propanoate Chemical compound C1=C(C)C(CCC(=O)OC)=CC=C1OCC[C@H](C)OC1=NC=C(Cl)C=C1C1=CC=CN=C1 OYBMNTODSPCODZ-SFHVURJKSA-N 0.000 description 1
- ADXFBSPPRMYLCE-IBGZPJMESA-N methyl 3-[4-[(3s)-3-[4-ethyl-2-(1,3-oxazol-2-yl)phenoxy]butoxy]-2-methylphenyl]propanoate Chemical compound C([C@H](C)OC1=CC=C(C=C1C=1OC=CN=1)CC)COC1=CC=C(CCC(=O)OC)C(C)=C1 ADXFBSPPRMYLCE-IBGZPJMESA-N 0.000 description 1
- JQJOOGJNGNYROR-IBGZPJMESA-N methyl 3-[4-[(3s)-3-[4-ethyl-2-(1,3-thiazol-4-yl)phenoxy]butoxy]-2-methylphenyl]propanoate Chemical compound C([C@H](C)OC1=CC=C(C=C1C=1N=CSC=1)CC)COC1=CC=C(CCC(=O)OC)C(C)=C1 JQJOOGJNGNYROR-IBGZPJMESA-N 0.000 description 1
- WUCSDMWHCANXOQ-FQEVSTJZSA-N methyl 3-[4-[(3s)-3-[4-ethyl-2-(furan-2-yl)phenoxy]butoxy]-2-methylphenyl]propanoate Chemical compound C([C@H](C)OC1=CC=C(C=C1C=1OC=CC=1)CC)COC1=CC=C(CCC(=O)OC)C(C)=C1 WUCSDMWHCANXOQ-FQEVSTJZSA-N 0.000 description 1
- JRURVKHHOAVNLX-UHFFFAOYSA-N methyl 3-[4-[3-(2-benzoyl-4-ethylphenoxy)butylsulfanyl]-2-methylphenyl]propanoate Chemical compound C=1C=CC=CC=1C(=O)C1=CC(CC)=CC=C1OC(C)CCSC1=CC=C(CCC(=O)OC)C(C)=C1 JRURVKHHOAVNLX-UHFFFAOYSA-N 0.000 description 1
- HIAYYYUJJINCMP-UHFFFAOYSA-N methyl 3-[4-[3-(2-benzoyl-4-propan-2-ylphenoxy)butoxy]-2-methylphenyl]propanoate Chemical compound C1=C(C)C(CCC(=O)OC)=CC=C1OCCC(C)OC1=CC=C(C(C)C)C=C1C(=O)C1=CC=CC=C1 HIAYYYUJJINCMP-UHFFFAOYSA-N 0.000 description 1
- UBMXBDJTIPDQBG-UHFFFAOYSA-N methyl 3-[4-[3-(4-ethyl-2-phenylphenoxy)butoxy]-2-methylphenyl]propanoate Chemical compound C=1C=CC=CC=1C1=CC(CC)=CC=C1OC(C)CCOC1=CC=C(CCC(=O)OC)C(C)=C1 UBMXBDJTIPDQBG-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PEECTLLHENGOKU-UHFFFAOYSA-N n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=NC=C1 PEECTLLHENGOKU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 1
- 125000000627 niacin group Chemical group 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 150000003176 prostaglandin J2 derivatives Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- 239000013062 quality control Sample Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- UQPRIOPJZWWHBS-UHFFFAOYSA-N tert-butyl 2-(5-ethyl-2-methoxyphenyl)pyrrole-1-carboxylate Chemical compound CCC1=CC=C(OC)C(C=2N(C=CC=2)C(=O)OC(C)(C)C)=C1 UQPRIOPJZWWHBS-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- SWFSRMBSDMJGOK-UHFFFAOYSA-N thiadiazol-4-ol Chemical compound OC1=CSN=N1 SWFSRMBSDMJGOK-UHFFFAOYSA-N 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
- QNMBSXGYAQZCTN-UHFFFAOYSA-N thiophen-3-ylboronic acid Chemical compound OB(O)C=1C=CSC=1 QNMBSXGYAQZCTN-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/86—Unsaturated compounds containing keto groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/88—Unsaturated compounds containing keto groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/16—Unsaturated compounds
- C07C61/39—Unsaturated compounds containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/30—Unsaturated compounds
- C07C62/34—Unsaturated compounds containing ether groups, groups, groups, or groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49654903P | 2003-08-20 | 2003-08-20 | |
| PCT/US2004/024381 WO2005019151A1 (en) | 2003-08-20 | 2004-08-17 | Ppar modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007502815A true JP2007502815A (ja) | 2007-02-15 |
| JP2007502815A5 JP2007502815A5 (https=) | 2007-09-20 |
Family
ID=34216018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006523861A Pending JP2007502815A (ja) | 2003-08-20 | 2004-08-17 | Ppar調節因子 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20060257987A1 (https=) |
| EP (1) | EP1660428A1 (https=) |
| JP (1) | JP2007502815A (https=) |
| CA (1) | CA2536089A1 (https=) |
| WO (1) | WO2005019151A1 (https=) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505907A (ja) * | 2003-09-19 | 2007-03-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 4−((フェノキシアルキル)チオ)−フェノキシ酢酸および類似化合物 |
| JP2007505916A (ja) * | 2003-09-19 | 2007-03-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 4−((フェノキシアルキル)チオ)−フェノキシ酢酸および類似化合物 |
| JP2008509929A (ja) * | 2004-08-13 | 2008-04-03 | メタボレックス インコーポレーティッド | Pparの調節剤およびそれらの調製法 |
| JP2008513374A (ja) * | 2004-09-15 | 2008-05-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 4−((フェノキシアルキル)チオ)−フェノキシ酢酸および類似物 |
| JP2008531493A (ja) * | 2005-02-22 | 2008-08-14 | アバンテイス・フアルマ・エス・アー | 新規3−アリール−1,2−ベンゾイソオキサゾール誘導体、これを含む組成物およびその使用 |
| JP2010529098A (ja) * | 2007-06-05 | 2010-08-26 | ガルデルマ・リサーチ・アンド・デヴェロップメント | Ppar型受容体の活性化剤である新規な3‐フェニルプロパン酸誘導体、その製造方法、および化粧品組成物または医薬組成物におけるその使用 |
| JP2013533283A (ja) * | 2010-07-23 | 2013-08-22 | コネクシオス ライフ サイエンシズ プライベート リミテッド | Gpr40のアゴニスト |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03011558A (es) | 2001-06-12 | 2004-03-26 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
| MXPA05008600A (es) | 2003-02-13 | 2005-11-04 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de desordenes metabolicos. |
| US20080051418A1 (en) * | 2004-11-26 | 2008-02-28 | Tsuyoshi Maekawa | Arylalkanoic Acid Derivative |
| JP5084503B2 (ja) * | 2005-07-29 | 2012-11-28 | 武田薬品工業株式会社 | シクロプロパンカルボン酸化合物 |
| JP4324221B2 (ja) | 2005-08-26 | 2009-09-02 | 株式会社医薬分子設計研究所 | Pparアゴニスト活性を有する誘導体 |
| JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| UA95613C2 (ru) | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
| UY30288A1 (es) * | 2006-04-18 | 2007-08-31 | Janssen Pharmaceutica Nv | Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol |
| TW200838526A (en) | 2006-12-01 | 2008-10-01 | Astellas Pharma Inc | Carboxylic acid derivatives |
| US8278460B2 (en) | 2009-10-15 | 2012-10-02 | Concert Pharmaceuticals, Inc. | Substituted benzimidazoles |
| CN103429581B (zh) | 2012-01-12 | 2015-08-26 | 江苏恒瑞医药股份有限公司 | 多环类衍生物、其制备方法及其在医药上的应用 |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| HK1218720A1 (zh) | 2013-04-30 | 2017-03-10 | 欧缇托匹克公司 | 干粉制剂及使用方法 |
| CN103524518B (zh) * | 2013-06-07 | 2017-05-10 | Tcl集团股份有限公司 | 轮状四烯类荧光化合物、制备方法和应用及电致发光器件 |
| US9790237B2 (en) * | 2014-06-16 | 2017-10-17 | Johnson Matthey Public Limited Company | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| KR102681843B1 (ko) | 2017-09-22 | 2024-07-05 | 벡추라 인코포레이티드 | 스테아르산마그네슘을 갖는 건조 분말 조성물 |
| CN114901641B (zh) * | 2020-02-28 | 2025-06-17 | 四川科伦博泰生物医药股份有限公司 | 芳香族化合物及其药物组合物和用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002503202A (ja) * | 1996-02-02 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | 抗糖尿病薬 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES533668A0 (es) * | 1983-06-24 | 1985-10-01 | Yamanouchi Pharma Co Ltd | Un compuesto fenoxi |
| ATE451346T1 (de) * | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| EA200400011A1 (ru) * | 2001-06-07 | 2004-06-24 | Эли Лилли Энд Компани | Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar) |
| MXPA03011201A (es) * | 2001-06-07 | 2004-02-26 | Lilly Co Eli | Moduladores de receptores activados por proliferadores de persoxisomas. |
-
2004
- 2004-08-17 JP JP2006523861A patent/JP2007502815A/ja active Pending
- 2004-08-17 EP EP04779442A patent/EP1660428A1/en not_active Withdrawn
- 2004-08-17 WO PCT/US2004/024381 patent/WO2005019151A1/en not_active Ceased
- 2004-08-17 US US10/566,291 patent/US20060257987A1/en not_active Abandoned
- 2004-08-17 CA CA002536089A patent/CA2536089A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002503202A (ja) * | 1996-02-02 | 2002-01-29 | メルク エンド カンパニー インコーポレーテッド | 抗糖尿病薬 |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007505907A (ja) * | 2003-09-19 | 2007-03-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 4−((フェノキシアルキル)チオ)−フェノキシ酢酸および類似化合物 |
| JP2007505916A (ja) * | 2003-09-19 | 2007-03-15 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 4−((フェノキシアルキル)チオ)−フェノキシ酢酸および類似化合物 |
| JP4928941B2 (ja) * | 2003-09-19 | 2012-05-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 4−((フェノキシアルキル)チオ)−フェノキシ酢酸および類似化合物 |
| JP2008509929A (ja) * | 2004-08-13 | 2008-04-03 | メタボレックス インコーポレーティッド | Pparの調節剤およびそれらの調製法 |
| JP2008513374A (ja) * | 2004-09-15 | 2008-05-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 4−((フェノキシアルキル)チオ)−フェノキシ酢酸および類似物 |
| JP2008531493A (ja) * | 2005-02-22 | 2008-08-14 | アバンテイス・フアルマ・エス・アー | 新規3−アリール−1,2−ベンゾイソオキサゾール誘導体、これを含む組成物およびその使用 |
| JP2010529098A (ja) * | 2007-06-05 | 2010-08-26 | ガルデルマ・リサーチ・アンド・デヴェロップメント | Ppar型受容体の活性化剤である新規な3‐フェニルプロパン酸誘導体、その製造方法、および化粧品組成物または医薬組成物におけるその使用 |
| JP2013533283A (ja) * | 2010-07-23 | 2013-08-22 | コネクシオス ライフ サイエンシズ プライベート リミテッド | Gpr40のアゴニスト |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060257987A1 (en) | 2006-11-16 |
| CA2536089A1 (en) | 2005-03-03 |
| EP1660428A1 (en) | 2006-05-31 |
| WO2005019151A1 (en) | 2005-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007502815A (ja) | Ppar調節因子 | |
| ES2288982T3 (es) | Derivados de acido oxazolil-ariloxiacetico y su uso como agonistas ppar. | |
| US7192982B2 (en) | Modulators of peroxisome proliferator activated receptors | |
| DE602004011985T2 (de) | Modulatoren des peroxisomproliferatoraktivierten rezeptors | |
| US7572934B2 (en) | Substituted biphenyl GPR40 modulators | |
| JP2005509590A6 (ja) | ペルオキシソーム増殖因子活性化受容体の調節物質 | |
| KR20050030624A (ko) | Hppar 활성화제로서 사용되는 페닐알칸산 및페닐옥시알칸산 유도체 | |
| US7608639B2 (en) | Phenoxyether derivatives as PPAR modulators | |
| JP2004506721A (ja) | オキサゾリル−アリールプロピオン酸誘導体およびそのpparアゴニストとしての使用 | |
| EP1742902A1 (en) | Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof | |
| WO2004000789A9 (en) | Amide linker peroxisome proliferator activated receptor modulators | |
| WO2005105764A1 (en) | Butanoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications threreof | |
| MXPA06006829A (es) | Moduladores del receptor activado por el proliferador selectivo de peroxisoma. | |
| AU2002312147A1 (en) | Modulators of peroxisome proliferator activated receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070802 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070802 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110510 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120522 |